Taysha Gene Therapies Files Q3 2024 10-Q
Ticker: TSHA · Form: 10-Q · Filed: Nov 13, 2024 · CIK: 1806310
Sentiment: neutral
Topics: 10-Q, SEC Filing, Gene Therapy, Financials
TL;DR
Taysha Gene Therapies filed its Q3 2024 10-Q, showing financial and operational details.
AI Summary
Taysha Gene Therapies, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quarter. Key financial data and disclosures relevant to investors are presented, including information on liabilities and equity.
Why It Matters
This filing provides crucial financial and operational insights into Taysha Gene Therapies' performance during the third quarter of 2024, impacting investor decisions.
Risk Assessment
Risk Level: medium — As a gene therapy company, Taysha Gene Therapies operates in a high-risk, high-reward sector with significant regulatory and development hurdles.
Key Numbers
- 2024-09-30 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 2024-11-13 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Filer of the 10-Q
- 2024-09-30 (date) — End of the reporting period
- 2024-11-13 (date) — Filing date
- 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX 75247 (address) — Company's business and mailing address
FAQ
What is the primary business of Taysha Gene Therapies, Inc.?
Taysha Gene Therapies, Inc. is in the business of developing biological products, specifically gene therapies, as indicated by its SIC code 2836.
For which fiscal period is this 10-Q filing?
This 10-Q filing is for the period ended September 30, 2024.
When was this 10-Q filing submitted to the SEC?
The filing was submitted on November 13, 2024.
What is the company's stated fiscal year end?
The company's fiscal year ends on December 31.
Where is Taysha Gene Therapies, Inc. located?
The company's business and mailing address is 3000 Pegasus Park Drive, Suite 1430, Dallas, TX 75247.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on November 13, 2024 regarding Taysha Gene Therapies, Inc. (TSHA).